Physician profile
Kenneth Obi
NPI 1184853053
$33,499.21
in general payments reported to CMS, 2019-2025
36 companies · $4,989 in 2025
The $4,989 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,530 · 2020: $1,248 · 2021: $1,981 · 2022: $8,056 · 2023: $2,484 · 2024: $13K · 2025: $4,989.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Food and Beverage: $8,230 · Travel and Lodging: $2,124 · Education: $9.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,320.00 |
| Food and Beverage | $8,230.18 |
| Travel and Lodging | $2,123.99 |
| Education | $9.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $13,324.96 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $4,754.62 | 2022-2023 | Zeposia |
| Abbvie INC. | $4,579.89 | 2019-2025 | |
| Celgene Corporation | $1,883.24 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,770.78 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $978.64 | 2019-2025 | Entyvio, Gattex |
| Genzyme Corporation | $898.69 | 2022-2025 | |
| Janssen Biotech, INC. | $876.06 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Gilead Sciences, INC. | $805.01 | 2019-2025 | Livdelzi |
| Pfizer INC. | $708.88 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $528.06 | 2019-2025 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $411.04 | 2022-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $300.35 | 2019-2024 | |
| Madrigal Pharmaceuticals | $230.98 | 2024-2025 | Rezdiffra, Resmetirom |
| Nestle Healthcare Nutrition INC. | $173.77 | 2020-2023 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $167.42 | 2020-2023 | Rebyota |
| Ipsen Biopharmaceuticals, INC | $167.05 | 2024-2025 | Iqirvo |
| Allergan, INC. | $143.90 | 2019 | |
| Medtronic, INC. | $130.06 | 2021-2025 | Pillcam, Endoflip |
| Ardelyx, INC. | $118.73 | 2023-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $76.13 | 2024-2025 | Zenpep |
| Alfasigma USA, INC. | $72.76 | 2020-2022 | |
| Ucb, INC. | $56.93 | 2019-2020 | |
| Olympus America INC. | $53.98 | 2024 | Gastrointestinal Videoscope, Evis Exera III Colonovideoscope |
| Vivus LLC | $51.11 | 2021-2023 | Qsymia |
| Mallinckrodt Hospital Products INC. | $44.94 | 2025 | Terlivaz |
| Covidien Lp | $30.18 | 2019 | |
| Intra-Sana Laboratories | $29.28 | 2021-2022 | |
| Romark Laboratories, Lc | $25.97 | 2019-2020 | |
| Boston Scientific Corporation | $23.05 | 2022 | |
| Redhill Biopharma INC. | $17.08 | 2022 | |
| Evoke Pharma, INC. | $15.43 | 2022 | |
| Amag Pharmaceuticals, INC. | $15.41 | 2019 | |
| Braintree Laboratories, INC. | $13.96 | 2020 | |
| Dova Pharmaceuticals | $11.63 | 2019 | |
| Janssen Pharmaceuticals, INC | $9.24 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Obi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.